NEW!

Thursday, April 21
Scientific Platform Sessions
Meeting Schedule
3:30 p.m.–5:30 p.m. Scientific Platform Sessions
S51: Clinical Trials in Multiple
Sclerosis II
3:30 p.m. S51.001
Alemtuzumab-Treated Patients with
RRMS Demonstrate Durable Slowing of
Brain Volume Loss Over 5 Years Despite
Most Being Treatment-Free for 4 Years:
CARE-MS I and II Extension Study —
Sven Schippling, Jeffrey Cohen, Alasdair
Coles, D Alastair Compston, Edward Fox,
Massimo Filippi, Hans-Peter Hartung, Eva
Havrdova, Krzysztof Selmaj, Frederik Barkhof,
David Margolin, Karthinathan Thangavelu,
Douglas Arnold
3:45 p.m. S51.002
Treatment-Naive Patients with Active
RRMS Who Received Alemtuzumab
Demonstrate Durable Suppression of
New MRI Lesion Formation: 5-Year
Follow-Up of the CARE-MS I Study —
Douglas Arnold, Jeffrey Cohen, Alasdair
Coles, D Alastair Compston, Edward Fox,
Hans-Peter Hartung, Eva Havrdova, Krzysztof
Selmaj, David Margolin, Karthinathan
Thangavelu, Anthony Traboulsee
4:00 p.m. S51.003
Treatment-Naive Patients with Highly
Active RRMS Demonstrated Durable
Efficacy with Alemtuzumab over 5
Years —Stephen Krieger, Barry Singer,
Mark Freedman, Jan Lycke, Regina
Berkovich, David Margolin, Karthinathan
Thangavelu, Eva Havrdova
4:15 p.m. S51.004
Treatment-Naive Patients with
Active RRMS Demonstrate Durable
Improvements in Relapse and Disability
Following Treatment with Alemtuzumab:
5-Year Follow-Up of the CARE-MS I
Study —Volker Limmroth, Gavin Giovannoni,
Douglas Arnold, Jeffrey Cohen, Alasdair
Coles, Edward Fox, Hans-Peter Hartung, Eva
Havrdova, Krzysztof Selmaj, David Margolin,
Karthinathan Thangavelu, D Alastair
Compston
4:30 p.m. S51.005
Durable Efficacy in RRMS Patients
Receiving Two Annual Courses of
Alemtuzumab and No Additional
Treatment for 4 Years: Pooled Analysis
of CARE-MS I and II —Edward Fox,
Douglas Arnold, Jeffrey Cohen, Gavin
Giovannoni, Hans-Peter Hartung, Eva
Havrdova, Krzysztof Selmaj, Volker Limmroth,
David Margolin, Karthinathan Thangavelu,
Alasdair Coles
4:45 p.m. S51.006
Time Course of Glatiramer Acetate
Efficacy in Relapsing-Remitting Multiple
Sclerosis Patients in the Glatiramer
Acetate Low-Frequency Administration
(GALA) Study —Mat Davis, Natalia
Ashtamker, Joshua Steinerman, Volker
Knappertz
5:00 p.m. S51.007
Brain Volume As a Predictor of Disability
in Primary Progressive Multiple
Sclerosis: Evidence from the INFORMS
Trial —Jerry Wolinsky, Dieter Häring, Maria
Pia Sormani, Fred Lublin, David Miller, Mark
Freedman, Bruce Cree, Howard Weiner,
Catherine Lubetzki, Hans-Peter Hartung,
Xavier Montalban, Bernard Uitdehaag,
Martin Merschhemke, Bingbing Li, Norman
Putzki, Ludwig Kappos
5:15 p.m. S51.008
MRI Parameters As Predictors of Long-
Term Disease Outcome Over 8 Years in
RRMS Patients —Douglas Jeffery, Daniela
Piani Meier, Davorka Tomic, Dieter Häring,
Timothy Vollmer
S52: Clinical Epilepsy, Genetics,
and Devices
3:30 p.m. S52.001
Long-Term Outcome of Adults with
Medically Intractable Mesial Temporal
Lobe Seizures Treated with Responsive
Neurostimulation —Paul Van Ness, Tara
Crowder Skarpaas, Martha Morrell
3:45 p.m. S52.002
Effects of Low-Frequency Stimulation of
Anterior Piriform Cortex on Kainate-
Induced Seizures in Rats —Mohamad
Koubeissi, Arezou Bayat, Mark Skopin,
Mittilesh Siddu, Komei Tsuchiya, Sweta
Joshi, Sahar Jahan, Phillip Connell
4:00 p.m. S52.003
Validation of the Smartphone
Brain Scanner for the Detection of
Epileptiform Discharges Among Epilepsy
Outpatients in Bhutan —Erica McKenzie,
Andrew Lim, Edward Leung, Andrew Cole,
Rodrigo Zepeda Garcia, Alice Lam, Ronald
Thibert, Esther Bui, Damber Nirola, Sonam
Deki, Lhab Tshering, Liesly Lee, Sarah Clark,
Joseph Cohen, Jo Mantia, Kate Brizzi, Sarah
Wahlster, Tali Sorets, Mikkel Aagaard,
Arkadiusz Stopczynski, Lars Hansen, Sydney
Cash, Farrah Mateen
4:15 p.m. S52.004
Evaluating the Prevalence of
Neurological Autoantibodies Among
Patients with Epilepsy of Unknown
Etiology: Ongoing Prospective Study —
Divyanshu Dubey, Ryan Hays, Abdulradha
Alqallaf, Matthew Freeman, Kevin Chen, Kan
Ding, Mark Agostini, Steven Vernino
4:30 p.m. S52.005
Severe Epileptic Encephalopathy Is
a Frequent Neurological Comorbidity
of Children Affected by the MECP2
Duplication Syndrome —Danah Marafie,
Rebecca Schultz, Daniel Glaze, Alica
Goldman, Bernhard Suter
4:45 p.m. S52.006
Novel Knock-in Mouse Model of Genetic
Atp1a3 Dysfunction —Ashley Helseth,
Syed Adil, Molly Linabarger, Eric Arehart,
Nina Fainberg, Deepu Singh, William
Wetsel, Ute Hochgeschwender, Arsen
Hunanyan, Mohamad Mikati
5:00 p.m. S52.007
Sleep Homeostasis and NREM Slow
Wave Activity in Animal Models and
Humans with Focal or Generalized
Epilepsy —Rama Maganti, Eli Wallace,
Jesse Pfammater, Samantha Wright,
Melanie Boly, Benjamin Jones, Mensen
Armand, Mathew Jones, Giulio Tononi
5:15 p.m. S52.008
Hand Postures in Primary and Secondary
Generalized Tonic-Clonic Seizures: A
New Semiological Feature —Jason
Siegel, William Tatum
S53: Infectious Disease
3:30 p.m. S53.001
VZV Neurovasculitis in the Setting of a
Novel Adult-Onset Immunocompromised
State with Autoantibodies to Interferon
Alpha (anti-IFNα)—Rahila Ansari, Shivam
Mittal, Zerbe Christa, Lindsey Rosen, Steven
Holland, Robert Bonomo
3:45 p.m. S53.002
Post Infectious Neurological
Manifestations of Acute Dengue
Viral Fever - a Prospective Study from
India —Devashish Ruikar, Sita Sattaluri,
Mohandas Surath
4:00 p.m. S53.003
Survivors of Ebola Virus Disease Have
Persistent Neurological Deficits —Lauren
Bowen, Bryan Smith, Sally Steinbach,
Bridgette Billioux, Angela Summers, Shila
Azodi, Joan Ohayon, Matthew Schindler,
Avindra Nath
4:15 p.m. S53.004
Neurocognitive Impairment of HIV Elite
Controllers: Feature of Viral Suppression
and Inflammation? —Nisha Bhatia, Evelyn
Lee, Dietmar Fuchs, Magnus Gisslen, Henrik
Zetterberg, Alex Russell, Barbara Shacklett,
Richard Price, Serena Spudich
4:30 p.m. S53.005
Insulin Signaling Suppresses Virus
Replication and Neuroinflammation in
HIV/AIDS —Manmeet Mamik, Eugene
Asahchop, Yu Zhu, Brienne McKenzie,
William Branton, Christopher Power
4:45 p.m. S53.006
Neurologic Signs and Symptoms
Frequently Manifest in Acute HIV
Infection —Joanna Hellmuth, James
Fletcher, Victor Valcour, Eugène Kroon,
Jintanat Ananworanich, Jintana Intasan,
Sukalaya Lerdlum, Jared Narvid, Mantana
Pothisri, Isabel Allen, Shelly Krebs,
Bonnie Slike, Peeriya Prueksakaew, Linda
Jagodzinski, Suwanna Puttamaswin, Nittaya
Phanuphak, Serena Spudich
5:00 p.m. S53.007
Association Between Influenza
Vaccination and Development of
Guillain-Barré Syndrome in Adults:
A Vaccine Safety Datalink (VSD) and
Vaccine Adverse Event Reporting
System (VAERS) Study —Francisco
Gomez, Mohammad El-Ghanem, Abu Nasar,
Nizar Souayah
5:15 p.m. S53.008
Clinical, Biological and Radiological
Characteristics of Patients with Rocky
Mountain Spotted Fever Encephalitis —
Michael Bradshaw, Kelsey Ivey, Francesca
Bagnato, NgocHanh Vu, Sumit Pruthi, Karen
Bloch
3:30 p.m.–5:30 p.m.
S51 Clinical Trials in
Multiple Sclerosis II
S52 Clinical Epilepsy,
Genetics, and Devices
S53 Infectious Disease
C224 Primer of Behavioral
Neurology II
Director: Maria Gorno Tempini,
MD, PhD, San Francisco, CA
C225 Neurology Update IV
Director: Barney J. Stern, MD,
FAAN, Baltimore, MD
C226 Deep Brain Stimulation
Management II
Director: Jill L. Ostrem, MD,
San Francisco, CA
C227 Organize and Run a
Successful Code Stroke
System
Director: Enrique C. Leira, MD,
MS, FAAN, Iowa City, IA
C228 Neuromuscular Junction
Disorders II
Director: Laura Marie
Tormoehlen, MD,
Indianapolis, IN
C229 Hot Topics in Sleep
Neurology II
Director: Erik Kent St. Louis,
MD, FAAN, Rochester, MN
C230 Neurologic
Complications of Medical
and Surgical Therapies
Director: Sara E. Hocker, MD,
Rochester, MN
C231 Non-Alzheimer’s
Dementia II
Director: Gil Dan Rabinovici,
MD, San Francisco, CA
C232 Hot Topics in Headaches
and Related Disorders II
Director: Peter Goadsby, MD,
PhD, San Francisco, CA
5:30 p.m.–7:00 p.m.
Closing Party Happy Hour
148 2016 AAN Annual Meeting Abstract Listing